Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 17%
Hold 67%
Sell 6%
Strong Sell 0%

Bulls say

Amgen is poised for long-term growth with its diverse portfolio of flagship drugs in the biotechnology field. Recently launched drugs like Repatha, Aimovig, Lumakras, and Tezspire are expected to drive strong revenue growth in the coming years. Additionally, Amgen's successful execution in external business development, such as the acquisition of Onyx Pharmaceuticals, could further enhance its expansion prospects. While there are potential risks such as product commercial and supply chain risks, Amgen's innovative therapies and strong market position make it a sound investment.

Bears say

Amgen is facing multiple downside risks including (1) disappointing pipeline data, particularly from MariTide and olpasiran; (2) potential erosion of current products such as Repatha and Otezla; and (3) regulatory and pricing risks that could decrease investor interest. Additionally, upcoming catalysts in 2027/2028, such as oncology and I&I pipeline assets, may not be sufficient to drive significant growth, and its total revenues are projected to remain in the range of $36B-$38B due to potential losses of exclusivity for key products like Prolia/Xgeva, Kyprolis, and Otezla. As a result, the financial analyst has a negative outlook on Amgen's stock.

Amgen (AMGN) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 18 analysts, Amgen (AMGN) has a Hold consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $352.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $352.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.